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 Background Survivors of childhood leukemia and lymphoma experience high risks of second malignant neoplasms. 
We quantified such risk using a large dataset from 13 population-based cancer registries. 
 Methods  The registries provided individual data on cases of leukemia, Hodgkin lymphoma, and non-Hodgkin 
lymphoma occurring in children aged 0 – 14 years and on subsequent second malignant neoplasms for differ-
ent time periods from 1943 to 2000. Risks of second malignant neoplasms were assessed through standard-
ized incidence ratios (SIRs) and corresponding 95% confidence intervals (CIs), using the incidence rates in the 
general populations covered by the registries as a reference. Cumulative absolute risks were also calculated. 
  Results A total of 133 second malignant neoplasms were observed in 16 540 patients (12 731 leukemias, 1246 
Hodgkin lymphomas, and 2563 non-Hodgkin lymphomas) after an average follow-up of 6.5 years. The 
most frequent second malignancies after leukemia were brain cancer (19 cases, SIR = 8.52, 95% CI = 5.13 
to 13.3), non-Hodgkin lymphoma (nine cases, SIR = 9.41, 95% CI = 4.30 to 17.9), and thyroid cancer (nine 
cases, SIR = 18.8, 95% CI = 8.60 to 35.7); the most frequent after Hodgkin lymphoma were thyroid cancer 
(nine cases, SIR = 52.5, 95% CI = 24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% CI = 7.66 to 45.4), 
and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 95% CI = 12.5 to 74.0); and the most fre-
quent after non-Hodgkin lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% CI = 14.8 to 88.0) and 
brain cancer (four cases, SIR = 6.97, 95% CI = 1.90 to 17.9). Cumulative incidence of any second malignant 
neoplasm was 2.43% (95% CI = 1.09 to 3.78), 12.7% (95% CI = 8.29 to 17.2), and 2.50% (95% CI = 1.04 to 
3.96) within 30 years from diagnosis of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, 
respectively. 
  Conclusions  This population-based study provides, to our knowledge, the most precise and up-to-date estimates for 
relative and absolute risks of second malignant neoplasms after childhood leukemia and lymphoma. 
  J Natl Cancer Inst 2007;99: 790 – 800 
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 Survival after childhood cancer has improved greatly over the last 
three decades. Recent estimates of cumulative survival published 
since 2000 in Europe (1 – 6), United States (7), New Zealand (8), 
and Japan (9) show that 5-year cumulative survival for children 
with cancer ranges from a minimum of 66% in New Zealand to 
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more than 80% in Germany. It has been estimated that, in the 
United States, one in 570 young adults between the ages of 20 
and 34 years is a childhood cancer survivor (10). Because of the 
young age of this ever-growing population of survivors and their 
potential longevity, the study of delayed sequelae of childhood 
cancer and its therapy is of increasing importance. Survivors of 
child hood cancer are at higher risk of developing a second malig-
nant neoplasm than the general population. Increasing numbers 
of childhood cancer survivors are still alive when the aging pro-
cess naturally increases the risk of cancer incidence, adding to the 
risk caused by childhood cancer. 
 The most common tumor types in the pediatric age group 
(0 – 14 years) are leukemias, central nervous system cancers, and 
lymphomas. Recent estimates report annual European incidence 
rates for childhood leukemia and lymphoma of 44.8 and 15.5 per 
million child-years (standardized to the world standard popula-
tion) in 1990 to 1999, with statistically signifi cant annual increases 
of 0.7% and 1.3%, respectively, from 1970 to 1999 (6). In the 
United States, leukemia and lymphoma incidence rates were 47.8 
and 15.1 per million child - years (standardized to the United States 
standard population) in 2000 to 2003 (7). In Europe, the 5-year 
survival rate has improved to over 75% in the 1990s for both leu-
kemia and lymphoma (6), and in the United States the most recent 
5-year survival rates (for 1996 to 2002) reached 79.5% for leuke-
mia and 86.3% for lymphoma (7). 
 Childhood leukemia and lymphoma survivors are the largest 
population of childhood cancer survivors at increased risk of devel-
oping second malignant neoplasms. The aim of this study was to 
quantify this risk, in both relative and absolute terms, using data 
from a collaborative project involving 13 population-based regis-
tries. This study is, to our knowledge, the largest population-based 
study on this topic. 
 Methods 
 Data Sources 
 This study is part of an international multicenter study of second 
malignant neoplasms that includes data from 13 population-
based cancer registries (New South Wales, Australia; British 
Columbia, Manitoba, and Saskatchewan, Canada; Denmark; 
Finland; Iceland; Norway; Singapore; Slovenia; Zaragoza, Spain; 
Sweden; and Scotland) that have been in operation for at least 25 
years and that were able to provide high-quality data. There are 
no relevant differences in how individual registries collect their 
data: all the registries have contributed data to the series Cancer 
Incidence in Five Continents (11) and have similar and high pro-
portion of completeness. The population covered by these cancer 
registries was approximately 47 million in the 1990s. The regis-
tries contributed data for different time periods in the years 
1943 – 2000, with a median observation period of 32 years. This 
dataset partially overlaps with that used in a previous study (12) 
in the Nordic countries (Denmark, Finland, Iceland, Norway, 
and Sweden) that analyzed second malignant neoplasms after 
cancer in childhood and adolescence diagnosed in the period 
1943 – 1987. In particular, 32 of the 75 second malignancies con-
tributed to this study by the Nordic countries were already 
included in the earlier Nordic countries’ study (12). The data 
contributed by the Slovenian registry (10 cases) were also 
included in a previous publication (13). 
 Data were provided by each cancer registry on selected primary 
neoplasms occurring during childhood (0 – 14 years of age), 
in cluding age and sex of the subject, diagnosis and date of the 
fi rst malignant neoplasm, follow-up for vital status, and date and 
diagnosis of the second malignant neoplasm, if any. All children 
who survived at least 1 day after their fi rst neoplasm diagnosis 
entered the survivors’ cohort. Subjects were no longer followed 
up if a second malignant neoplasm had occurred or if they died, 
migrated out of the study area, or were lost to follow-up. Registries 
used different cancer codes that were systematically converted 
by the International Agency for Research on Cancer (IARC) to 
International Classifi cation of Diseases, 9th Revision (ICD-9) 
codes (14). We analyzed the occurrence of second malignant neo-
plasms in patients who were diagnosed with leukemia (ICD-9: 
204 – 208), Hodgkin lymphoma (ICD-9: 201), or non-Hodgkin 
lymphoma (ICD-9: 200, 202) between 0 and 14 years of age and 
who survived for at least one day. Coding of multiple primary can-
cers followed a common set of rules proposed by the International 
Association of Cancer Registries and the IARC (15). According to 
these rules, a primary cancer is one that originates in a primary site 
or tissue and is thus not an extension, a recurrence, or a metastasis. 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 The population of survivors of childhood cancer is growing and 
aging. Hematolymphopoietic malignancies are among the most 
common cancers of childhood. 
 Study design 
 Population-based registry study in which 13 registries from around 
the world provided individual data on more than 16  500 survivors 
of childhood leukemia, Hodgkin lymphoma, and non-Hodgkin lym-
phoma. Rates of second malignancies in survivors were compared 
with those in the general populations covered by the registries. 
 Contributions 
 After an average follow-up of 6.5 years, survivors had almost seven 
times the risk of a second malignant neoplasm than the general 
population. The most frequent second malignancies after leukemia 
were brain cancer, non-Hodgkin lymphoma, and thyroid cancer; 
after Hodgkin lymphoma were thyroid cancer, female breast can-
cer, and nonmelanoma skin cancer; and after non-Hodgkin lym-
phoma were thyroid cancer and brain cancer. Cumulative incidence 
of any second cancer 30 years after diagnosis of leukemia, Hodgkin 
lymphoma, and non-Hodgkin lymphoma was 2.4%, 12.7%, and 
2.5%, respectively. 
 Implications 
 Survivors of hematolymphopoietic neoplasms are at increased risk 
of second cancers, with survivors of Hodgkin lymphoma at particu-
larly high risk. Both relative and absolute risks could be evaluated 
in this large and geographically diverse study. 
 Limitations 
 Individual treatment information was not available from the registries. 
Because of small numbers and multiple comparisons, some 
associations may have arisen by chance. Some misclassification is 
possible. 
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To exclude recurrences, we did not analyze the occurrence of 
leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma after 
childhood leukemia, Hodgkin lymphoma, and non-Hodgkin 
lymphoma, respectively. Cancers in the same patient occurring 
after the fi rst second malignant neoplasm were not analyzed. In 
situ cancers were not considered to be second primaries. The 
Saskatchewan registry in Canada did not provide data on non-
melanoma skin cancers. 
 All data were provided in an anonymous fashion with respect 
to patient identities. Approval for the study was obtained from the 
ethics committee of IARC. Informed consent was not required 
because the study was based on anonymized registry records. 
 Statistical Analysis 
 To assess the excess of second malignant neoplasms after child-
hood leukemia or lymphoma, we calculated standardized incidence 
ratios (SIRs) and corresponding 95% confidence intervals (CIs) of 
all second malignant neoplasms. These were calculated as the ratio 
of the observed number of second malignant neoplasms to the 
expected number, which was obtained by applying the age-, sex-, 
year-, and registry-specific incidence rates of first primary cancers 
to the population of survivors of the childhood malignancies under 
study (16). The reference population is the general population 
covered by the registries involved in the study. Standardized inci-
dence ratios were calculated for all types of second malignant neo-
plasms by length of follow-up, age at first neoplasm diagnosis, and 
calendar period of first neoplasm registration (before and after 
1980, approximately at the middle of the observation period). 
The absolute excess risk was calculated as the difference between 
observed second malignant neoplasms and expected number of 
cases of each cancer type, divided by the total number of person-
years at risk. 
 Cumulative incidence of second malignant neoplasms in the 
survivors’ cohort was calculated by taking into account death from 
any cause as a competing risk event (17). The observed cumulative 
incidence was estimated nonparametrically in a two-step process: 
both the Kaplan – Meier estimate of the overall survival from any 
event (second malignant neoplasm or death) and the conditional 
probability of second malignant neoplasm were computed. The 
cumulative incidence of second malignant neoplasms was then 
computed by summing the products of the overall survival and the 
hazard rate of second malignant neoplasm for all time intervals. 
Expected cumulative incidence was calculated using the life-table 
method (18) without considering competing risks. The entire 
follow-up period was divided into consecutive 5-year intervals, and 
the probability of survival within each interval, defi ned as being free 
from a second malignant neoplasm, was calculated by dividing the 
expected number of second malignant neoplasm – free individuals 
in the interval by the number of fi rst neoplasm survivors who were 
alive and free from a second malignant neoplasm at the beginning 
of the interval. This numerator was adjusted for censoring, i.e., 
second malignant neoplasm – free individuals who died in the inter-
val counted for half an individual in the numerator. The expected 
cumulative probability of being second malignant neoplasm–free 
after a given follow-up duration was the product of the probabili-
ties during the relevant intervals, and its complement was the 
expected cumulative incidence of second malignant neoplasms. 
The effect of death as a competing risk in the general population 
was assumed to be negligible, given the young age range consid-
ered in our analysis: 0 – 14 years at diagnosis plus an average follow-
up time of 6.5 years. Only 4.7% of the follow-up time of the 
cohort comprised subjects more than 40 years of age. The stan-
dardized death rate for all causes reported in the European mortal-
ity database of the World Health Organization for people aged 
1 – 19 years in 2004 was 21.6 per 100  000 (19). All statistical tests 
were two-sided. The Breslow–Day test was used to assess stan-
dardized incidence ratios heterogeneity between registries and 
trends by age-group (20). 
 Results 
 A total of 12  731 survivors of leukemia, 1246 survivors of Hodgkin 
lymphoma, and 2563 survivors of non-Hodgkin lymphoma, con-
tributing 108  171 person-years of observation, were identified from 
the pool of 13 registries. The mean follow-up time was 6.5 years. 
During follow-up, a total of 133 second malignant neoplasms were 
recorded. The median age and follow-up time at the occurrence 
of a second malignant neoplasm were 16.0 (interquartile range 
[IQR] = 10.0 – 24.0) and 9.5 (IQR = 4.70 – 16.3) years after leukemia 
and 26.0 (IQR = 20.0 – 32.0) and 16.3 (IQR = 9.30 – 22.2) years after 
lymphoma, respectively. The distribution of first neoplasms ac -
cording to various characteristics and the corresponding number 
of second malignant neoplasms are shown in  Table 1 . 
 Table 2 reports the number of observed and expected second 
malignant neoplasms and the corresponding standardized incidence 
ratios and absolute excess risks (per 100  000 person-years), in survi-
vors of leukemia, Hodgkin lymphoma, and non-Hodgkin lym-
phoma (separately), for neoplasms with at least one observed case. 
The overall standardized incidence ratio for having a second malig-
nant neoplasm after any childhood hematolymphopoietic neoplasm 
was 6.77 (95% CI = 5.67 to 8.02). The most frequent second malig-
nant neoplasms after leukemia were brain cancer (19 cases, SIR = 
8.52, 95% CI = 5.13 to 13.3), non-Hodgkin lymphoma (nine cases, 
SIR = 9.41, 95% CI = 4.30 to 17.9) and thyroid cancer (nine cases, 
SIR = 18.8, 95% CI = 8.60 to 35.7); the most frequent after Hodgkin 
lymphoma were thyroid cancer (nine cases, SIR = 52.5, 95% CI = 
24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% CI = 7.66 to 
45.4), and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 
95% CI = 12.5 to 74.0); and the most frequent after non-Hodgkin 
lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% CI = 14.8 
to 88.0) and brain cancer (four cases, SIR = 6.97, 95% CI = 1.90 to 
17.9). Elevated standardized incidence ratios were found for 14 
neoplasm types, namely cancers of the tongue, salivary glands, liver, 
bone, female breast, bladder, brain, thyroid, soft tissue sarcoma, 
nonmelanoma skin cancer, Hodgkin lymphoma, non-Hodgkin 
lymphoma, myeloid leukemia, and other leukemias. 
 When considering the six registries contributing most person-
years to the dataset, standardized incidence ratios for all second 
malignant neoplasms ranged from 3.30 (95% CI = 1.06 to 7.70) in 
Finland (fi ve cases) to 9.94 (95% CI = 5.56 to 16.4) in New South 
Wales (15 cases) after leukemia, from 6.21 (95% CI = 1.67 to 15.9) 
in Sweden (four cases) to 13.3 (95% CI = 6.07 to 25.2) in Denmark 
(nine cases) after Hodgkin lymphoma, and from 1.42 (95% CI = 
0.02 to 7.90) in Norway (one case) to 4.91 (95% CI = 0.55 to 17.7) 
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 Table 1.  Distribution of childhood first malignant neoplasms (leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma) and number 
of second malignant neoplasms (in parentheses), by selected characteristics 
 Characteristics 
First malignant neoplasm 
 Leukemia Hodgkin lymphoma Non-Hodgkin lymphoma 
 Sex  
  Female 5662 (28) 422 (23) 806 (10) 
  Male 7069 (39) 824 (25) 1757 (8) 
 Age at first neoplasm registration, y  
  <1 318 (0) 0 (0) 79 (0) 
  1 – 4 5949 (32) 81 (5) 686 (1) 
  5 – 9 4061 (24) 378 (10) 927 (10) 
  10 – 14 2403 (11) 787 (33) 871 (7) 
 Calendar period at first neoplasm diagnosis  
  Before 1970 2666 (3) 240 (16) 442 (3) 
  1970 – 1979 3201 (29) 295 (20) 629 (6) 
  1980 – 1989 3694 (29) 387 (11) 802 (6) 
  1990 or later 3170 (6) 324 (1) 690 (3) 
 Duration of follow-up, y  
  <1 3754 (4) 122 (1) 890 (2) 
  1 – 4 4225 (14) 295 (2) 576 (4) 
  5 – 9 1787 (18) 246 (9) 325 (2) 
  10 – 14 1258 (8) 181 (7) 282 (2) 
  15 – 19 956 (15) 170 (10) 227 (2) 
  20 – 24 559 (4) 116 (9) 116 (4) 
  25 – 29 135 (3) 68 (7) 70 (2) 
  30 – 34 29 (1) 28 (2) 29 (0) 
  35 – 39 18 (0) 12 (0) 27 (0) 
  ³ 40 10 (0) 8 (1) 21 (0) 
 Registry (registration period)  
  New South Wales, Australia (1972 – 1997) 1466 (15) 145 (5) 309 (2) 
  British Columbia, Canada (1970 – 1998) 780 (6) 98 (3) 169 (1) 
  Manitoba, Canada (1970 – 1998) 301 (0) 40 (3) 79 (0) 
  Saskatchewan, Canada (1967 – 1998) 289 (1) 28 (1) 55 (1) 
  Denmark (1943 – 1997) 2064 (10) 173 (9) 399 (6) 
  Finland (1953 – 1998) 1946 (5) 187 (7) 305 (2) 
  Iceland (1955 – 2000) 106 (0) 14 (0) 14 (0) 
  Norway (1953 – 1999) 1764 (7) 131 (7) 286 (1) 
  Singapore (1968 – 1992) 591 (0) 33 (1) 128 (0) 
  Slovenia (1961 – 1998) 447 (5) 94 (4) 85 (1) 
  Zaragoza, Spain (1978 – 1998) 120 (0) 16 (0) 49 (0) 
  Sweden (1961 – 1998) 2019 (14) 187 (4) 524 (3) 
  Scotland (1975 – 1996) 838 (4) 100 (4) 161 (1) 
 Total 12 731 (67) 1246 (48) 2563 (18) 
in New South Wales (two cases) after non-Hodgkin lymphoma. 
Heterogeneity among registries was not statistically signifi cant. 
 Table 3 shows standardized incidence ratios of second malig-
nant neoplasms by period of diagnosis (i.e., before and after 1980) 
of childhood leukemia and Hodgkin lymphoma diagnosis. There 
were nine second malignant neoplasms after non-Hodgkin lym-
phoma diagnosed before 1980 (SIR = 2.75, 95% CI = 1.26 to 5.21) 
and nine cases after non-Hodgkin lymphoma diagnosed after 1980 
(SIR = 5.83, 95% CI = 2.67 to 11.1). 
 Table 4 shows standardized incidence ratios of the most fre-
quent (at least fi ve observed cases) second malignant neoplasms in 
survivors of childhood leukemia, Hodgkin lymphoma, and non-
Hodgkin lymphoma considered together by the time elapsed since 
the diagnosis of the fi rst neoplasm. In survivors of childhood leu-
kemia, most brain cancers (16 out of 19) occurred between 1 and 
14 years after diagnosis of the fi rst neoplasm (with a peak at 5 – 9 
years after diagnosis), seven out of nine of non-Hodgkin lympho-
mas occurred between 1 and 9 years after diagnosis, and eight out 
of nine thyroid cancers occurred between 10 and 19 years after 
diagnosis (data not shown). Standardized incidence ratios of brain 
cancer and non-Hodgkin lymphoma exhibited a bell-shaped dis-
tribution, whereas those of thyroid cancer increased steadily with 
time since leukemia diagnosis (data not shown). In survivors of 
childhood Hodgkin lymphoma, all thyroid cancers but one (which 
occurred in the fi rst 12 months) occurred at least 10 years after 
diagnosis, all neoplasms of the skin (other than melanoma) but one 
(which occurred 5 – 9 years after diagnosis) occurred at least 15 
years after diagnosis, all breast cancers occurred at least 10 years 
after diagnosis, all myeloid leukemias occurred 5 – 19 years after 
diagnosis, and all the other leukemias occurred within 9 years after 
the original Hodgkin lymphoma diagnosis. In survivors of non-
Hodgkin lymphoma, all thyroid cancers occurred at least 10 years 
after diagnosis, whereas three out of four brain cancers occurred 
within 4 years of diagnosis. 
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 Table 2.  Standardized incidence ratios with 95% confidence intervals and absolute excess risks per 100  000 person-years of selected 
second malignant neoplasms after childhood leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma * 
 Neoplasm sites 
[ICD-9 code (14)] † 
First malignant neoplasm (person-years at risk) 
 Leukemia (75  212) Hodgkin lymphoma (14  074) Non-Hodgkin lymphoma (18  886) 
 O E SIR (95% CI) AER ‡ O E SIR (95% CI) AER ‡ O E SIR (95% CI) AER ‡ 
 All malignant 
 neoplasms 
 (140 – 208)
67 10.9 6.12 (4.74 to 7.77) 74.5 48 3.88 12.4 (9.12 to 16.4) 313.5 18 4.82 3.73 (2.21 to 5.90) 69.8 
 Tongue (141) 2 0.03 71.9 (8.70 to 260) 2.6 0 0.02 0.00 (0.00 to 234)  − 0.1 0 0.02 0.00 (0.00 to 215)  − 0.1 
 Salivary gland (142) 2 0.06 31.5 (3.81 to 114) 2.6 0 0.02 0.00 (0.00 to 170)  − 0.1 0 0.02 0.00 (0.00 to 172)  − 0.1 
 Esophagus (150) 0 0.01 0.00 (0.00 to 556) 0.0 1 0.01 120 (3.00 to 669) 7.0 0 0.01 0.00 (0.00 to 313)  − 0.1 
 Small intestine (152) 0 0.02 0.00 (0.00 to 233) 0.0 0 0.01 0.00 (0.00 to 358)  − 0.1 1 0.01 105 (2.62 to 583) 5.2 
 Colon (153) 0 0.24 0.00 (0.00 to 15.4)  − 0.3 1 0.11 9.23 (0.23 to 51.4) 6.3 1 0.13 7.48 (0.19 o 41.7) 4.6 
 Rectum (154) 0 0.05 0.00 (0.00 to 75.8)  − 0.1 1 0.04 22.3 (0.56 to 124) 6.8 0 0.06 0.00 (0.00 to 66.0)  − 0.3 
 Liver (155) 
 (excluding 155.2)
2 0.08 24.6 (2.98 to 89.0) 2.6 0 0.02 0.00 (0.00 to 165)  − 0.1 1 0.03 34.7 (0.87 to 194) 5.1 
 Pancreas (157) 0 0.03 0.00 (0.00 to 118) 0.0 1 0.02 44.4 (1.11 to 247) 7.0 0 0.03 0.00 (0.00 to 123)  − 0.2 
 Lung (162) 0 0.10 0.00 (0.00 to 35.2)  − 0.1 2 0.08 23.7 (2.87 to 85.6) 13.6 0 0.12 0.00 (0.00 to 30.8)  − 0.6 
 Bone (170) 3 0.60 5.03 (1.04 to 14.7) 3.2 1 0.14 6.99 (0.17 to 39.0) 6.1 1 0.18 5.56 (0.14 to 31.0) 4.3 
 Soft tissue 
 sarcoma (171)
2 0.48 4.13 (0.50 to 14.9) 2.0 2 0.11 17.8 (2.16 to 64.4) 13.4 0 0.14 0.00 (0.00 to 26.1)  − 0.7 
 Melanoma of 
 skin (172)
2 1.05 1.91 (0.23 to 6.89) 1.3 3 0.45 6.71 (1.38 to 19.6) 18.1 0 0.47 0.00 (0.00 to 7.83)  − 2.5 
 Other neoplasm 
 of skin (173)
4 0.28 14.3 (3.91 to 36.7) 4.9 6 0.18 34.0 (12.5 to 74.0) 41.4 1 0.25 3.94 (0.10 to 21.9) 4.0 
 Female breast (174) 1 0.41 2.42 (0.06 to 13.5) 0.8 6 0.29 20.9 (7.66 to 45.4) 40.6 0 0.33 0.00 (0.00 to 11.0)  − 1.7 
 Testis (186) 2 0.86 2.32 (0.28 to 8.37) 1.5 0 0.50 0.00 (0.0 to 7.31)  − 3.6 0 0.51 0.00 (0.00 to 7.19)  − 2.7 
 Other male genital than 
 testis (187)
0 0.01 0.00 (0.00 to 271) 0.0 1 0.01 142 (3.56 to 794) 7.0 0 0.01 0.00 (0.00 to 421)  − 0.1 
 Bladder (188, 
 189.3, 189.4)
4 0.07 53.6 (14.6 to 137) 5.2 0 0.05 0.00 (0.00 to 67.3)  − 0.4 0 0.07 0.00 (0.00 to 51.7)  − 0.4 
 Kidney (189) 
 (excluding 
 189.3, 189.4)
1 0.36 2.75 (0.07 to 15.3) 0.9 0 0.06 0.00 (0.00 to 65.1)  − 0.4 0 0.10 0.00 (0.00 to 36.1)  − 0.5 
 Brain, nervous 
 system (191–192)
19 2.23 8.52 (5.13 to 13.3) 22.3 3 0.39 7.76 (1.60 to 22.7) 18.5 4 0.57 6.97 (1.90 to 17.9) 18.2 
 Thyroid gland (193) 9 0.48 18.8 (8.60 to 35.7) 11.3 9 0.17 52.5 (24.0 to 99.6) 62.7 6 0.15 40.4 (14.8 to 88.0) 31.0 
 Other endocrine gland 
 (194, 164)
1 0.18 5.56 (0.14 to 31.0) 1.1 0 0.03 0.00 (0.00 to 132)  − 0.2 0 0.04 0.00 (0.00 to 86.8)  − 0.2 
 Hodgkin 
 lymphoma (201)
4 1.04 3.85 (1.05 to 9.86) 3.9 NA NA NA NA 2 0.35 5.77 (0.70 to 20.8) 8.7 
 Non-Hodgkin 
 lymphoma (200, 202)
9 0.96 9.41 (4.30 to 17.9) 10.7 1 0.26 3.83 (0.10 to 21.3) 5.3 NA NA NA NA 
 Lymphoid 
 leukemia (204)
NA NA NA NA 0 0.13 0.00 (0.00 to 27.3)  − 0.9 1 0.23 4.36 (0.11 to 24.3) 4.0 
 Myeloid leukemia (205) NA NA NA NA 4 0.12 33.9 (9.24 to 86.8) 27.6 0 0.12 0.00 (0.00 to 29.9)  − 0.6 
 Other leukemia 
 (206–208)
NA NA NA NA 5 0.09 53.7 (17.4 to 125) 34.9 0 0.21 0.00 (0.00 to 17.8)  − 1.1 
 *  ICD-9 = International Classification for Diseases, 9th Revision; O = observed; E = expected; SIR = standardized incidence ratio; CI = confidence interval; 
AER = absolute excess risk; NA = not applicable: incidence of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma after childhood leukemia, Hodgkin 
lymphoma, and non-Hodgkin lymphoma, respectively, were not analyzed. 
 †  Second malignant neoplasms with at least one observed case for any of the three first neoplasm types. 
 ‡  Per 100  000 person-years. 
 Most second malignant neoplasms occurred in patients who 
had been diagnosed with childhood leukemia when they were 
1 – 4 years old (data not shown), as expected because childhood 
leukemia incidence peaks at approximately 3 years of age (6). 
Among survivors of Hodgkin lymphoma, secondary breast cancer 
and myeloid leukemia occurred exclusively in patients who had 
their fi rst neoplasm when they were 10 – 14 years old (data not 
shown). Incidence of thyroid cancer decreased with increasing age 
at fi rst diagnosis (age 1 – 4 years: four cases, SIR = 797 [95% CI = 
217 to 2041]; 5 to 9 years: three cases, SIR = 87.1 [95% CI = 18.0 
to 254]; 10 to 14 years: two cases, SIR = 15.1 [95% CI = 1.83 to 
54.7]; test for trend:  P <.001). Incidence of other leukemias 
increased with increasing age at fi rst diagnosis (zero cases in the 
age-group 1 – 4 years; one case in the age-group 5 – 9 years, SIR = 
30.1 [95% CI = 0.75 to 167]; four cases in the age-group 10 – 14 
years, SIR = 79.3 [95% CI = 21.6 to 203]; test for trend:  P = .23). 
 Cumulative incidence of second malignant neoplasms in survi-
vors of childhood leukemia or lymphoma is shown in  Fig. 1 . The 
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 Table 3 .  Standardized incidence ratios and corresponding confidence intervals of selected second malignant neoplasms after 
childhood leukemia and Hodgkin lymphoma, by calendar period of diagnosis of childhood first malignant neoplasm * 
 Neoplasm sites [ICD-9 code (14)] † 
Calendar period of first neoplasm diagnosis 
 Before 1980 1980 or later 
 O E SIR (95% CI) O E SIR (95% CI) 
 Leukemia ‡  
  All malignant neoplasms (140 – 208) 32 5.73 5.58 (3.82 to 7.88) 35 5.22 6.71 (4.67 to 9.33) 
  Tongue (141) 2 0.02 101 (12.2 to 364) 0 0.01 0.00 (0.00 to 367) 
  Salivary gland (142) 0 0.03 0.00 (0.00 to 122) 2 0.03 66.8 (8.08 to 241) 
  Liver (155) (excluding 155.2) 2 0.03 60.5 (7.32 to 219) 0 0.05 0.00 (0.00 to 73.4) 
  Bone (170) 1 0.24 4.17 (0.10 to 23.2) 2 0.36 5.60 (0.68 to 20.2) 
  Soft tissue sarcoma (171) 0 0.2 0.00 (0.00 to 18.3) 2 0.29 6.99 (0.85 to 25.2) 
  Melanoma of skin (172) 1 0.71 1.41 (0.04 to 7.87) 1 0.34 2.93 (0.07 to 16.4) 
  Other neoplasms of skin (173) 3 0.19 15.7 (3.23 to 45.7) 1 0.09 11.4 (0.29 to 63.8) 
  Female breast (174) 1 0.40 2.53 (0.06 to 14.1) 0 0.02 0.00 (0.00 to 183) 
  Testis (186) 0 0.54 0.00 (0.00 to 6.79) 2 0.33 6.15 (0.74 to 22.2) 
  Bladder (188, 189.3, 189.4) 3 0.05 56.9 (11.7 to 166) 1 0.02 45.7 (1.14 to 254) 
  Kidney (189) (excluding 189.3, 189.4) 1 0.14 7.10 (0.18 to 39.6) 0 0.22 0.00 (0.00 to 16.7) 
  Brain, nervous system (191 – 192) 6 0.79 7.60 (2.79 to 16.6) 13 1.44 9.02 (4.80 to 15.4) 
  Thyroid gland (193) 5 0.29 17.0 (5.53 to 39.8) 4 0.19 21.6 (5.88 to 55.3) 
  Other endocrine glands (194, 164) 0 0.05 0.00 (0.00 to 73.4) 1 0.13 7.94 (0.20 to 44.2) 
  Hodgkin lymphoma (201) 3 0.49 6.14 (1.27 to 17.9) 1 0.55 1.82 (0.05 to 10.1) 
  Non-Hodgkin lymphoma (200, 202) 4 0.39 10.3 (2.81 to 26.4) 5 0.57 8.79 (2.85 to 20.5) 
 Hodgkin lymphoma §  
  All malignant neoplasms (140 – 208) 36 2.81 12.8 (8.97 to 17.7) 12 1.07 11.2 (5.79 to 19.6) 
  Esophagus (150) 1 0.01 130 (3.24 to 723) 0 <0.01 0.00 (0.00 to 6148) 
  Colon (153) 1 0.09 11.7 (0.29 to 65.1) 0 0.02 0.00 (0.00 to 183) 
  Rectum (154) 1 0.04 24.0 (0.60 to 134) 0 <0.01 0.00 (0.00 to 1230) 
  Pancreas (157) 1 0.02 48.7 (1.22 to 272) 0 <0.01 0.00 (0.00 to 1845) 
  Lung (162) 2 0.08 25.8 (3.13 to 93.4) 0 0.01 0.00 (0.00 to 367) 
  Bone (170) 1 0.08 13.2 (0.33 to 73.3) 0 0.07 0.00 (0.00 to 52) 
  Soft tissue sarcoma (171) 2 0.07 29.4 (3.56 to 106) 0 0.04 0.00 (0.00 to 92) 
  Melanoma of skin (172) 3 0.32 9.27 (1.91 to 27.1) 0 0.12 0.00 (0.00 to 31) 
  Other neoplasms of skin (173) 5 0.15 34.0 (11.0 to 79.2) 1 0.03 34.1 (0.85 to 190) 
  Female breast (174) 6 0.27 21.9 (8.03 to 47.6) 0 0.01 0.00 (0.00 to 367) 
  Other male genital than testis (187) 1 0.01 173 (4.33 to 966) 0 <0.01 0.00 (0.00 to 3689) 
  Brain, nervous system (191 – 192) 1 0.23 4.39 (0.11 to 24.5) 2 0.16 12.6 (1.52 to 45.5) 
  Thyroid gland (193) 6 0.12 51.4 (18.9 to 112) 3 0.05 54.7 (11.3 to 160) 
  Non-Hodgkin lymphoma (200, 202) 0 0.17 0.00 (0.00 to 21.6) 1 0.09 10.6 (0.26 to 58.9) 
  Myeloid leukemia (205) 2 0.08 26.1 (3.16 to 94.5) 2 0.04 48.3 (5.84 to 174) 
  Other leukemia (206 – 208) 2 0.06 35.7 (4.32 to 129) 3 0.04 80.8 (16.7 to 236) 
 *  ICD-9 = International Classification of Diseases, 9th Revision; O = observed; E = expected; SIR = standardized incidence ratio; CI = confidence interval. 
 †  Second malignant neoplasms with at least one observed case. 
 ‡  Person-years at risk were 30  678 for the period before 1980 and 44  534 for 1980 or later. 
 §  Person-years at risk were 8148 for the period before 1980 and 5926 for 1980 or later. 
cumulative incidence of any malignancy within 30 years since the 
fi rst neoplasm diagnosis was 2.43% (95% CI = 1.09 to 3.78) after 
leukemia, three times the expected cumulative incidence of any 
malignancies in the general population; 12.7% (95% CI = 8.29 to 
17.2) after Hodgkin lymphoma, 11 times the expected incidence; 
and 2.50% (95% CI = 1.04 to 3.96) after non-Hodgkin lymphoma, 
2.5 times the expected incidence. The cumulative incidence 
reached 3.40% (95% CI = 1.12 to 5.68) 35 years after leukemia, 
and 31.9% (95% CI = 20.1 to 43.7) 45 years after Hodgkin 
lymphoma. 
 Discussion 
 In this study of second cancers after childhood leukemia and lym-
phoma, we found that survivors had an increased risk of developing 
a second malignant neoplasm compared with the general population. 
The highest risk was found in Hodgkin lymphoma survivors, 
confirming previous findings from population-based and clinical 
studies (12,13,21 – 33). The most frequent second malignant neo-
plasms were, in descending order, brain cancer, non-Hodgkin lym-
phoma, and thyroid cancer after leukemia; thyroid cancer, female 
breast cancer, and non-melanoma skin cancer after Hodgkin lym-
phoma; and thyroid cancer and brain cancer after non-Hodgkin 
lymphoma. 
 Large cohorts of childhood cancer survivors have been studied 
to estimate the risk of developing a second malignant neoplasm 
and to disentangle the role of various risk factors (i.e., factors 
related to the host, initial cancer type, and cancer therapies) (21). 
The main risk factors for second malignant neoplasms in survivors 
of childhood cancer are radiotherapy and chemotherapy (34). At 
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least 80% of second malignant neoplasms in childhood cancer sur-
vivors develop in the radiotherapy fi eld, with a median latency 
of at least 10 years and no risk plateau (35). Different tissues are 
not equally sensitive to radiation, and host factors such as repair 
enzymes, rate of cell division, endocrine, and immune function may 
be important cofactors. For a given radiation dose, orthovoltage 
(voltage in the range of 140 – 400 kV) in use until the middle of the 
1970s and the 1980s was more oncogenic than megavoltage (volt-
age > 1 MV) (35,36). Other possible risk factors include rare 
genetic/host predisposition to developing multiple cancers and 
underlying factors common to different diseases or treatment, such 
as immunosuppression due to infection with human immunodefi -
ciency virus or bone marrow transplantation (36). Environmental 
and behavioral shared risk factors are less likely to have played a 
role in the development of a second malignant neoplasm after child-
hood hematolymphopoietic neoplasms, given the short latency 
of childhood cancer. 
 Individual treatment information was not available from the 
registries contributing data to our study, and hence no causal 
in ference on the effects of therapies can be drawn. Nevertheless, 
knowledge of temporal changes in treatment practice in pediatric 
hematology may help the interpretation of our results, if it is 
assumed that intercountry variations in treatment procedures 
were small among the high-income countries of the 13 cancer 
registries included in our analysis. Similar trends in survival after 
childhood cancer in European countries and the United States 
confi rm a general uniformity of procedures and treatments 
(37,38). 
 Among second malignant neoplasms that may be related to 
radiotherapy are brain, thyroid, breast, and nonmelanoma skin 
cancers (36). Brain cancers are the most common second malig-
nant neoplasms after lymphoid leukemia, with a median latency of 
7 – 11 years (25,39,40). A causal link between brain cancer and cra-
nial irradiation has been suggested (41). In the 1970s and 1980s, 
cranial and spinal radiotherapy was used with doses in the range 
of 18 – 24 Gy as prophylaxis to central nervous system involve-
ment (42,43). In addition, brain cancers have been reported in 
children who had lymphoid leukemia and were not treated with 
radiotherapy (44). Thyroid cancer induced by radiation is fre-
quently observed in long-term survivors of childhood cancer, 
although it is not a leading cause of death among them. Those 
treated for childhood cancer before age 10 years have the highest 
risk (45). The frequency of thyroid cancer increases linearly with 
radiation doses up to 30 Gy and decreases at higher doses (46). 
In the 1970s and 1980s, children treated for lymphoid leukemia 
received small quantities of radiation at the thyroid because of the 
unclear borders of the cranial irradiation fi eld (42,43), whereas 
children with lymphomas were often treated with supradiaphrag-
matic radiotherapy (including mediastinal, sovraclavear, and lat-
erocervical nodes) (47). Patients treated with radiotherapy also 
have increased risk of developing nonmelanoma skin neoplasms in 
the treatment fi eld (48). Second malignant neoplasms are a lead-
ing cause of death among long-term survivors of Hodgkin lym-
phoma, and breast cancer is the most frequent second malignant 
neoplasm among female survivors (32). A previous study found 
that the risk starts to increase 5 – 9 years after completion of 
radiotherapy, is highest among girls treated at an age of 10 years 
or older, and is lower for women diagnosed when they were more 
than 30 years of age (49). The effect of radiation is likely to be 
stronger during puberty, when breast cells proliferate rapidly 
due to the hormonal stimulation, resulting in an increased risk of 
 Fig. 1 .  Cumulative incidence (%) of second malignant neoplasms after 
childhood leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma 
by time since childhood fi rst malignant neoplasm diagnosis.  Error bars 
represent 95% confi dence intervals. ( Y -axis scale differs for Hodgkin 
lymphoma.) 
0
0 10 20 30 40 50
0 10 20 30 40 50
0 10 20 30 40 50
1
2
3
4
5
6
Years since leukemia
C
um
ul
at
iv
e 
in
ci
de
nc
e 
(%
)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
(%
)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
(%
)
observed
expected
observed
expected
0
10
20
30
40
50
Years since Hodgkin lymphoma
0
1
2
3
4
5
6
Years since non-Hodgkin lymphoma
observed
expected
 at U
ni Torino D
ip Sanità Pubblica M
icrobiologia on A
pril 3, 2012
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
798   Articles | JNCI Vol. 99, Issue 10  |  May 16, 2007
developing breast cancer. The main concern for Hodgkin lym-
phoma survivors is thus the risk of subsequent breast cancer among 
adolescents and young women treated with supradiaphragmatic 
radiotherapy (47). Recently, it was estimated that cumulative 
absolute risks of breast cancer after Hodgkin lymphoma range 
from 0% to 39.6% (based on 3817 women diagnosed up to 30 
years of age), depending on age at Hodgkin lymphoma diagnosis, 
duration of follow-up, and type of treatment. For patients diag-
nosed by 15 years of age who received a mediastinal dose of at 
least 40 Gy and no alkylating agents, the cumulative projected risk 
of breast cancer at 30 years of follow-up was 10.3% (95% 
CI = 6.8% to 15.2%) (50). Women treated with radiotherapy or 
alkylating agents and who had early menopause (i.e., before age 
40 years) had a lower risk of breast cancer than those who main-
tained normal ovarian function (51). 
 In our study, all six breast cancers occurred 10 – 29 years after a 
Hodgkin lymphoma diagnosis among women who were 10 – 14 
years of age at the time of the fi rst diagnosis and who had 
originally been diagnosed before 1980 (when radiotherapy was 
used intensively). This pattern is consistent with the radiosensitiv-
ity of the breast at ages near puberty. The estimated cumulative 
incidence of any second malignant neoplasm among Hodgkin 
lymphoma survivors was 12.7% (95% CI = 8.29% to 17.2%) and 
31.9% (95% CI = 20.1% to 43.7%) at 30 and 45 years of follow-up, 
respectively. These fi ndings highlight the importance of careful 
follow-up of long-term Hodgkin lymphoma survivors. However, 
therapies that may be related to the high estimated risk of second 
malignant neoplasms in these women were in use two to three 
decades ago and do not refl ect the optimal treatment protocols in 
use currently, which, by using lower doses and smaller radiother-
apy fi elds, are expected to decrease the risk of late effects (52,53). 
Radiation therapy may also be related to risk of head and neck 
cancers. In a recent report (54), elevated risk of head and neck 
neoplasms (SIR = 20.9, 95% CI = 10.5 to 41.8, based on eight 
cases) was found in 4834 patients who survived childhood leuke-
mia. In the group of patients for whom radiation therapy data 
were available, this treatment was associated with head and neck 
carcinomas. 
 With regard to chemotherapy, secondary acute myeloid leuke-
mia is the most frequent hematologic second malignant neoplasm 
among Hodgkin lymphoma survivors (55). In our study, we found 
an increased risk for myeloid leukemia among Hodgkin lymphoma 
survivors (SIR = 33.9, 95% CI = 9.24 to 86.8, based on four cases). 
MOPP (mechloretamine, vincristine, prednisone, and procarba-
zine), the standard chemotherapy for Hodgkin lymphoma in the 
1970s and the early 1980s, has been linked to increased risk of sec-
ondary leukemias, with a plateau 10 – 14 years after the end of the 
therapy (23,24). In the early 1980s, treatment procedures shifted 
from intense to less aggressive radiotherapy and the introduction 
of less leukemogenic chemotherapy (such as ABVD [adriamycin, 
bleomycin, vinblastine, and dacarbazine]) (36). Recently, an ele-
vated risk of bladder cancer (SIR = 10.6, 95% CI = 2.7 to 42.3, 
based on two cases) was found in a cohort of 4834 childhood leu-
kemia survivors (54). An increased risk of bladder cancer in adults 
has been associated with cyclophosphamide, which is often used to 
treat non-Hodgkin lymphomas (56,57) and, more rarely, child-
hood leukemia (58). 
 In our study, we found that childhood cancer survivors had 
increased risk for second malignant neoplasms that have been 
associated with radiotherapy (cancers of the brain, thyroid, skin 
[nonmelanoma], breast, and head and neck [the tongue and sali-
vary glands in particular]) and chemotherapy (acute nonlym-
phocytic leukemia and bladder cancer). Although we cannot draw 
conclusions on the causative role of treatments on second malig-
nancies, the risk pattern that emerges from our study is generally 
consistent with the late effects of therapies for childhood cancer in 
use during the study period. 
 This study allowed a precise and up-to-date estimation of 
cumulative incidence of second malignant neoplasms after child-
hood hematolymphopoietic neoplasms. The cumulative incidence 
of any malignancies for survivors ranged from 2.43% (95% CI = 
1.09 to 3.78) 30 years after leukemia to 31.9% (95% CI = 20.1 to 
43.7) 45 years after Hodgkin lymphoma. Compared with the gen-
eral population, survivors of childhood Hodgkin lymphoma had 
an 11-fold increased risk of having any malignancy in 30 years 
since the fi rst neoplasm diagnosis. Cumulative incidence of second 
malignant neoplasms was higher for children who had a leukemia 
or lymphoma diagnosed after 1980. This phenomenon may be 
related to the more intensive and aggressive chemotherapies that 
have been used in more recent years as opposed to less toxic 
although less effective therapies before 1980. 
 The data analyzed in this study came from 13 well-established 
cancer registries and form a large dataset for a population-based 
study of second malignant neoplasms in childhood cancer survi-
vors. Nevertheless, several possible limitations have to be consid-
ered in interpreting our results, including the small number of 
second malignant neoplasms, the possibility of chance associa-
tions due to multiple comparisons, and misclassifi cation due to the 
unspecialized coding used to classify childhood cancer. However, 
for the fi rst primary malignancies considered in this work, conver-
sion between ICD-9 and childhood cancer classifi cation is straight-
forward, and, because second malignant neoplasms may occur 
several years after the fi rst neoplasm, adult cancer classifi cation 
may be the appropriate one to use for many of the second malig-
nant neoplasms identifi ed. 
 In addition, the analysis of lymphoid leukemia data was not 
possible in our study. Reliable diagnoses of lymphoid leukemia 
are available starting from the 1970s (59), whereas some of the 
registries included cases diagnosed as early as 1943. The number 
of lymphoid leukemias, which generally account for approxi-
mately 80% of all leukemias in children, was therefore likely to 
be underestimated. The analysis of the lymphoid leukemia sub-
group, however, yielded risk estimates of second malignant neo-
plasms that were essentially identical to those for all leukemias 
but less precise because of the smaller number of events (data not 
shown). 
 Sometimes more than one second malignant neoplasm occurs 
in childhood cancer survivors. In this study, underestimation of the 
total number of malignancies following a primary neoplasm should 
therefore be expected because the study design implied that sub-
jects exited from the cohort after the occurrence of one second 
malignant neoplasm. 
 The major strength of this population-based study is the size of 
the cohort, which has provided a unique opportunity to evaluate 
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both the relative and the absolute risks of second malignant neo-
plasms for long-term survivors. The geographical heterogeneity 
of the registries contributing to this study and the high quality 
of their data make the described pattern of second malignant 
neoplasm risk for childhood leukemia and lymphoma survivors 
valid for many areas in the world. Extensive efforts are still needed 
to collect information on the long-term risk of second cancers in 
the increasingly large and aging population of childhood cancer 
survivors. A thorough understanding of the epidemiology of sec-
ond cancers is essential for developing preventive strategies (60) 
targeted at individuals who survived childhood cancer. 
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